Doximity, Inc. $DOCS Shares Acquired by M&G PLC

M&G PLC grew its position in Doximity, Inc. (NYSE:DOCS) by 96.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 577,196 shares of the company’s stock after buying an additional 283,296 shares during the quarter. M&G PLC owned 0.32% of Doximity worth $16,161,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Signaturefd LLC raised its stake in shares of Doximity by 10.4% during the 3rd quarter. Signaturefd LLC now owns 4,205 shares of the company’s stock worth $119,000 after acquiring an additional 397 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Doximity by 59.9% in the third quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the company’s stock worth $53,000 after purchasing an additional 695 shares during the last quarter. Apella Capital LLC increased its position in shares of Doximity by 1.4% during the third quarter. Apella Capital LLC now owns 59,488 shares of the company’s stock worth $1,647,000 after purchasing an additional 802 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Doximity by 19.8% during the third quarter. GAMMA Investing LLC now owns 5,834 shares of the company’s stock worth $165,000 after purchasing an additional 963 shares in the last quarter. Finally, Parallel Advisors LLC lifted its holdings in shares of Doximity by 111.0% during the 1st quarter. Parallel Advisors LLC now owns 2,560 shares of the company’s stock valued at $60,000 after purchasing an additional 1,347 shares during the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Insider Buying and Selling

In other Doximity news, Director Kira Wampler sold 2,000 shares of Doximity stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $32.89, for a total transaction of $65,780.00. Following the completion of the transaction, the director owned 27,923 shares in the company, valued at approximately $918,387.47. This trade represents a 6.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Siddharth Sitaram sold 2,613 shares of the business’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $30.68, for a total value of $80,166.84. Following the completion of the transaction, the chief accounting officer directly owned 101,432 shares of the company’s stock, valued at approximately $3,111,933.76. This trade represents a 2.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 24,471 shares of company stock valued at $761,545 over the last quarter. 31.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

DOCS has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised their price objective on Doximity from $26.00 to $31.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Freedom Capital cut shares of Doximity from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Needham & Company LLC reissued a “buy” rating and set a $41.00 target price on shares of Doximity in a research report on Friday, November 6th. BMO Capital Markets restated a “market perform” rating and set a $30.00 price target on shares of Doximity in a research note on Friday, August 7th. Finally, Royal Bank Of Canada upped their price target on shares of Doximity from $28.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, November 6th. Eight analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $30.45.

More Doximity News

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Some analysts have raised Doximity’s price targets, including Canaccord Genuity to $40, and Needham reiterated its Buy rating. A recent report also highlighted adoption of Doximity’s AI search products by 16 of the top 20 pharmaceutical companies and 34% year-over-year growth in quarterly active workflow prescribers. Analyst price target report Doximity long-term investor takeaways
• Neutral Sentiment: Director Timothy Cabral sold 10,721 shares for about $375,000. The transaction was made under a pre-arranged Rule 10b5-1 plan, which may make it less informative as a signal about his current outlook. Insider transaction report
• Negative Sentiment: Multiple law firms publicized a securities class action covering shares purchased from August 8, 2024, through May 13, 2026, with a November 16 deadline to seek lead-plaintiff status. The complaint alleges Doximity misled investors about market-share losses, competition and advertising practices, including reliance on lower-engagement formats, as well as revenue and growth trends. These claims have not been proven, but the litigation adds uncertainty and could weigh on sentiment. Class action allegations and deadline Advertising disclosure allegations

Doximity Price Performance

DOCS stock opened at $32.45 on Wednesday. The firm’s fifty day simple moving average is $29.33 and its 200-day simple moving average is $25.43. The company has a market capitalization of $5.78 billion, a P/E ratio of 45.07, a price-to-earnings-growth ratio of 34.25 and a beta of 1.29. Doximity, Inc. has a 12 month low of $17.15 and a 12 month high of $54.04.

Doximity (NYSE:DOCS) last issued its earnings results on Thursday, November 5th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.17. Doximity had a net margin of 21.12% and a return on equity of 15.80%. The firm had revenue of $174.54 million during the quarter. During the same period last year, the business earned $0.45 EPS. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. As a group, sell-side analysts forecast that Doximity, Inc. will post 0.74 earnings per share for the current year.

Doximity Profile

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.